Safety of Chinese Herbal Medicine for Chronic Obstructive Pulmonary Disease

Abstract EN

Chinese herbal medicine (CHM) is increasingly used by patients with chronic obstructive pulmonary disease (COPD); however, there has been no systematic evaluation of its safety.

This review examined the adverse events (AEs) reported in clinical studies of CHM for COPD.

Five English databases (PubMed, Embase, CINAHL, AMED, and CENTRAL) and four Chinese databases (CBM, CNKI, CQVIP, and Wanfang Data) were searched from inception to May 2013.

Adverse event data, including nature, severity, author-assigned causality, management, and outcome, were extracted from included studies.

Descriptive statistics were used for the rate of adverse events.

Of the 152 included studies, AEs were reported in 47 studies.

The rate of adverse events was slightly lower in the CHM groups compared with controls (84 events in 5,909 participants, 1.4% versus 102 events in 5,676 participants, 1.8%).

The most frequently reported adverse event was nausea (28 cases in the CHM groups and 19 cases in the control groups), which was more common in studies where CHM was combined with pharmacotherapy to treat acute exacerbation of COPD.

Other frequent adverse events were abdominal discomfort, dry mouth, and dizziness.

Detailed information about the adverse events was scant.

Overall, CHM appears to be well tolerated in people with COPD.